कंपनी का अवलोकन
Cibus, Inc. (CBUS) operates as an agricultural biotechnology enterprise focused on the development and licensing of gene-edited plant traits designed to enhance agricultural productivity. The company functions within the broader healthcare sector, specifically under the biotechnology industry sub-segment, where it seeks to provide sustainable ingredients and solutions that allow farmers to reduce reliance on chemical inputs such as fungicides, insecticides, and fertilizers. As of the latest available data, the organization employs a workforce of 118 individuals and holds a total market capitalization of $101.83M, while reporting trailing twelve-month (TTM) revenue of $3.64M. These valuation and revenue figures indicate that Cibus functions as a small-cap biotechnology entity with limited revenue scale relative to its market cap, suggesting a capital-intensive business model typical of early-stage biotech firms that prioritize research and development over immediate profitability.
वित्तीय स्वास्थ्य
The company reported TTM revenue of $3.64M alongside a significant net income loss of $127,085,000 and an EBITDA of $-61,541,000, revealing a substantial divergence between top-line sales and bottom-line profitability that highlights an aggressive or inefficient cost structure. The firm generated free cash flow of $-51,790,624, which indicates a negative cash conversion where operating expenses and capital expenditures exceed cash inflows from sales, thereby limiting immediate financial flexibility for expansion or acquisitions. Analyzing the profit margins reveals a gross margin of 100.0%, suggesting no cost of goods sold relative to revenue in this reporting period, contrasted sharply by an operating margin of -1273.3% and a profit margin of 0.0%, which collectively point to severe operational inefficiencies or high overhead costs relative to sales volume. On the liability side, Cibus holds $9.92M in cash against $267.96M in debt, resulting in a debt-to-equity ratio of 1227.56, which signifies an extremely leveraged balance sheet with a high risk of insolvency should cash flows not improve. The current ratio stands at 0.72, indicating that the company's current assets are insufficient to cover its current liabilities, reflecting potential short-term liquidity constraints. Furthermore, the return on equity is -221.0% and the return on assets is -12.9%, metrics that demonstrate that management is currently destroying shareholder value and failing to generate returns on the capital invested in the company's assets.
मूल्यांकन आकलन
The valuation metrics for Cibus show a P/E Ratio (TTM) of N/A due to the absence of positive earnings, while the forward P/E is listed at -6.30, implying that future earnings projections remain negative or that the market prices the stock based on non-earnings fundamentals. The price-to-book ratio is 3.13, indicating that the market values the company's equity at more than three times its book value, which may reflect high expectations for future gene-editing success or a premium placed on its intellectual property despite current losses. Alternative valuation multiples such as the price-to-sales ratio of 27.98 and an EV/EBITDA of -5.61 suggest that investors are pricing the stock based on revenue potential rather than profitability, a common practice for biotechnology companies in the development phase. Regarding trading range, the stock has a 52-week high of $4.19 and a 52-week low of $1.09, meaning the current price sits significantly below the annual peak and reflects the high volatility inherent in small-cap biotech stocks. The stock exhibits a beta of 1.93, which means its price is expected to be nearly twice as volatile as the broader market, amplifying both potential gains and losses during periods of market turbulence.
Growth & Income
Cibus experienced a revenue growth year-over-year of -12.8%, while earnings growth is marked as N/A due to the company's negative earnings history, indicating that the decline in revenue is the primary driver of financial contraction rather than a shift in earnings dynamics. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that all available cash is retained to fund operations or pay down debt rather than being distributed to shareholders. Given the substantial debt load and negative free cash flow, the lack of dividend payments is a necessity for survival rather than a strategic choice to reinvest in growth, as the company lacks the profitability to sustain a payout. Overall, the growth and income profile of Cibus is characterized by declining revenue, zero income distribution, and a reliance on external capital or asset monetization to navigate its current financial challenges.